New insights into MLL gene rearranged acute leukemias using gene expression profiling:: shared pathways, lineage commitment, and partner genes

被引:68
作者
Kohlmann, A
Schoch, C
Dugas, M
Schnittger, S
Hiddemann, W
Kern, W
Haferlach, T
机构
[1] Univ Munich, Dept Internal Med 3, Lab Leukemia Diagnost, D-81377 Munich, Germany
[2] Univ Munich, Dept Med Informat Biometr & Epidemiol, Munich, Germany
关键词
acute leukemia; gene expression; microarray; MLL; t(11q23);
D O I
10.1038/sj.leu.2403746
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Rearrangements of the MLL gene occur in both acute lymphoblastic and acute myeloid leukemias ( ALL, AML). This study addressed the global gene expression pattern of these two leukemia subtypes with respect to common deregulated pathways and lineage- associated differences. We analyzed 73 t( 11q23)/ MLL leukemias in comparison to 290 other acute leukemias and demonstrate that 11q23 leukemias combined are characterized by a common specific gene expression signature. Additionally, in unsupervised and supervised data analysis algorithms, ALL and AML cases with t( 11q23) segregate according to the lineage they are derived from, that is, myeloid or lymphoid, respectively. This segregation can be explained by a highly differing transcriptional program. Through the use of novel biological network analyses, essential regulators of early B cell development, PAX5 and EBF, were shown to be associated with a clear B- lineage commitment in lymphoblastic t( 11q23)/ MLL leukemias. Also, the influence of the different MLL translocation partners on the transcriptional program was directly assessed. Interestingly, gene expression profiling did not reveal a clear distinct pattern associated with one of the analyzed partner genes. Taken together, the identified molecular expression pattern of MLL fusion gene samples and biological networks revealed new insights into the aberrant transcriptional program in 11q23/ MLL leukemias.
引用
收藏
页码:953 / 964
页数:12
相关论文
共 63 条
[1]   Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy [J].
Almasan, A ;
Ashkenazi, A .
CYTOKINE & GROWTH FACTOR REVIEWS, 2003, 14 (3-4) :337-348
[2]   Inhibition of FLT3 in MLL: Validation of a therapeutic target identified by gene expression based classification [J].
Armstrong, SA ;
Kung, AL ;
Mabon, ME ;
Silverman, LB ;
Stam, RW ;
Den Boer, ML ;
Pieters, R ;
Kersey, JH ;
Sallan, SE ;
Fletcher, JA ;
Golub, TR ;
Griffin, JD ;
Korsmeyer, SJ .
CANCER CELL, 2003, 3 (02) :173-183
[3]   MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia [J].
Armstrong, SA ;
Staunton, JE ;
Silverman, LB ;
Pieters, R ;
de Boer, ML ;
Minden, MD ;
Sallan, SE ;
Lander, ES ;
Golub, TR ;
Korsmeyer, SJ .
NATURE GENETICS, 2002, 30 (01) :41-47
[4]   The interferon-inducible p200 family of proteins: a perspective on their roles in cell cycle regulation and differentiation [J].
Asefa, B ;
Klarmann, KD ;
Copeland, NG ;
Gilbert, DJ ;
Jenkins, NA ;
Keller, JR .
BLOOD CELLS MOLECULES AND DISEASES, 2004, 32 (01) :155-167
[5]   Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins [J].
Ayton, PM ;
Cleary, ML .
ONCOGENE, 2001, 20 (40) :5695-5707
[6]   Biological and therapeutic aspects of infant leukemia [J].
Biondi, A ;
Cimino, G ;
Pieters, R ;
Pui, CH .
BLOOD, 2000, 96 (01) :24-33
[7]   Human CREB-binding protein/p300-interacting transactivator with ED-rich tail (CITED) 4, a new member of the CITED family, functions as a co-activator for transcription factor AP-2 [J].
Bragança, J ;
Swingler, T ;
Marques, FIR ;
Jones, T ;
Eloranta, JJ ;
Hurst, HC ;
Shioda, T ;
Bhattacharya, S .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (10) :8559-8565
[8]   Knowledge-based analysis of microarray gene expression data by using support vector machines [J].
Brown, MPS ;
Grundy, WN ;
Lin, D ;
Cristianini, N ;
Sugnet, CW ;
Furey, TS ;
Ares, M ;
Haussler, D .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (01) :262-267
[9]   Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia [J].
Bullinger, L ;
Döhner, K ;
Bair, E ;
Fröhling, S ;
Schlenk, RF ;
Tibshirani, R ;
Döhner, H ;
Pollack, JR .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (16) :1605-1616
[10]   Transcriptional control of early B cell development [J].
Busslinger, M .
ANNUAL REVIEW OF IMMUNOLOGY, 2004, 22 :55-79